Exosome therapy & extracellular vesicles

Exosomes and other extracellular vesicles (EVs) are nanoscale membrane vesicles (roughly 30-150 nm) secreted by nearly all human cell types, naturally carrying lipids, proteins, mRNA and microRNA between cells as a form of intercellular communication. The field splits into two parallel tracks: native EVs purified from mesenchymal stem cells (MSCs) for their inherent anti-inflammatory and regenerative properties without the oncogenicity or embolism risk of live-cell therapy, and engineered EVs loaded with therapeutic cargo (siRNA, mRNA, proteins or CRISPR-Cas9 components) and surface-modified to target specific tissues. Evox Therapeutics (UK) has developed its DeliverEX platform specifically to engineer and load exosomes with RNA payloads and gene-editing tools including CRISPR-Cas9 for targeted delivery to difficult-to-reach tissue. Capricor Therapeutics is furthest along in the clinic among the companies here, though its lead asset, Deramiocel (formerly CAP-1002), is technically an allogeneic cardiosphere-derived cell therapy rather than an isolated exosome product — its anti-inflammatory benefit in Duchenne muscular dystrophy is believed to work partly through paracrine exosome secretion, and the company’s BLA is now scheduled for an FDA Advisory Committee review on July 29, 2026, backed by five-year HOPE-2 Open-Label Extension data and Phase 3 HOPE-3 trial results. Aegle Therapeutics is running a Phase 1/2a trial of AGLE-102, an MSC-derived extracellular-vesicle therapy, in patients with dystrophic epidermolysis bullosa, having dosed its first patient and reported positive initial safety data. Anjarium Biosciences (Switzerland) is developing hybrid vesicles that combine synthetic DNA constructs with vesicle-based delivery for cell and gene therapy applications. Underpinning the whole field, the International Society for Extracellular Vesicles (ISEV) maintains the MISEV guidelines (most recently updated as MISEV2023) that define the minimal characterization standards — nomenclature, purity verification, membrane-marker confirmation — that both EMA and FDA lean on when evaluating EV-based products.

The key directions of exosome therapy and extracellular vesicles are:

1. Native (unmodified) exosomes: purified vesicles from human mesenchymal stem cells, valued for the anti-inflammatory, immunomodulatory and regenerative properties of the parent cell without live-cell therapy risks.
2. Engineered (loaded) exosomes: vesicles used as biocompatible nanocontainers for targeted delivery of therapeutic cargo — siRNA, mRNA, therapeutic proteins or CRISPR-Cas9 systems — with surface-modified targeting ligands.
3. Hybrid vesicles: artificially assembled particles combining native-exosome biocompatibility with synthetic-nanoparticle cargo capacity, aiming to overcome the loading-capacity limits of pure exosomes.
4. Standardized characterization: internationally agreed criteria (ISEV’s MISEV guidelines) for confirming a preparation is genuinely composed of exosomes at defined purity, size and membrane-marker profile.

Sectoral value chain#

[MSC/donor-cell culture] ──> [Supernatant harvest & TFF concentration] ──> [Ultracentrifugation / chromatography purification]
                │                                        │                                          │
       (Bioreactor, suspension)                 (Primary clarification)                    (Ultra-pure vesicles)
                                                                                                       │
[Finished GMP product] <──── [Fill/finish & potency assay] <─── [Cargo loading (electroporation/sonication)] <──┘

Value chain levels#

Cross-cutting technologies of the sector:

• Nanoparticle tracking analysis (NTA): laser-illuminated video microscopy that tracks Brownian motion of individual vesicles and applies the Einstein-Stokes equation to calculate each particle’s hydrodynamic diameter and the batch’s precise particle concentration.
• Exosome electroporation: brief microsecond electrical pulses that transiently open pores in the vesicle’s lipid bilayer in the presence of a concentrated therapeutic cargo, allowing cargo to enter before the pores self-seal.
• Hollow-fiber bioreactor culture: donor cells grow in the extracapillary space of a bundle of porous hollow-fiber membranes, with perfused media supplying nutrients while secreted vesicles accumulate at very high concentration outside the fiber lumen, simplifying downstream purification.

The extracellular-vesicle production and characterization stack pairs specialized bioreactor and purification hardware with precision analytical instrumentation to verify vesicle identity and purity:

1. Hollow-fiber bioreactor culture:
   • Donor cells (e.g. cord-derived MSCs or HEK293 cells) populate the extracapillary space of a dense bundle of porous hollow-fiber membranes; secreted vesicles cannot pass back through the small fiber pores and instead accumulate at very high concentration in the extracapillary space, sharply reducing the downstream concentration burden.
2. High-performance size-exclusion chromatography (SEC):
   • Concentrated vesicle preparations pass through porous polymer resin beads; larger exosomes elute first in the column’s free volume while smaller free proteins and DNA fragments are retained longer in the resin pores, achieving gentle separation without the pressure that could rupture fragile lipid membranes.
3. Nanoparticle tracking analysis (NTA):
   • A focused laser beam illuminates individual vesicles in a diluted sample, and software tracks each particle’s Brownian-motion trajectory frame by frame to calculate its diffusion coefficient and diameter, building a detailed particle-size-distribution profile for batch release.